Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND Study
2024-511951-16-00Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Proportion of neuropsychiatric grade 2-4 adverse effects. Started May 2024; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-511951-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511951-16-00.